Citi raised the firm’s price target on Tandem Diabetes (TNDM) to $22 from $16 and keeps a Neutral rating on the shares. Citi also added a “downside 90-day catalyst watch” on the shares. The firm sees 2026 expectations as too high going into the company’s initial outlook.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target raised to $23 from $17 at Morgan Stanley
- Tandem Diabetes Care Appoints Sandra Beaver to Board
- Tandem Diabetes price target raised to $17 from $13 at Morgan Stanley
- Tandem Diabetes receives FDA clearance for use with Android smartphones
- Tandem Diabetes Care Q3 2025 Earnings: Record Sales & Growth